liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease
Karolinska University Hospital, Stockholm, Sweden.
Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Neurology.
Molde Hospital HNR, Norway .
Sahlgrenska University Hospital, Gothenburg, Sweden.
Show others and affiliations
2012 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 126, no 6, e29-e33 p.Article in journal (Refereed) Published
Abstract [en]

Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, andgt;= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months.

Place, publisher, year, edition, pages
John Wiley & Sons, 2012. Vol. 126, no 6, e29-e33 p.
Keyword [en]
movement disorders, Parkinsons disease, quality of life, treatment
National Category
Engineering and Technology
Identifiers
URN: urn:nbn:se:liu:diva-85843DOI: 10.1111/j.1600-0404.2012.01689.xISI: 000310545400001OAI: oai:DiVA.org:liu-85843DiVA: diva2:573293
Note

Funding Agencies|Abbott Laboratories, Abbott Park, IL, USA||Abbott||Swedish Parkinsons Disease Foundation||Swedish Research Council||Ostergotland County Council||Liber AB||Kibion AB||Selanders Foundation||Swedish Society for Medical Research||Uppsala University||

Available from: 2012-11-30 Created: 2012-11-30 Last updated: 2017-06-19

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Dizdar, Nil

Search in DiVA

By author/editor
Dizdar, Nil
By organisation
Department of Neurology
In the same journal
Acta Neurologica Scandinavica
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 50 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf